Bioxel Pharma Inc.

Bioxel Pharma Inc.

October 10, 2007 14:25 ET

Bioxel Builds Momentum in Europe With Significant Paclitaxel Order from Leading Generic Company

SAINTE-FOY, QUEBEC--(Marketwire - Oct. 10, 2007) - Bioxel Pharma Inc. (TSX VENTURE:BIP), a leading manufacturer and supplier of taxane APIs, is pleased to announce today that it has landed a significant paclitaxel order with a leading EU generic manufacturing company. The order, valued at $700,000, will be used in a generic paclitaxel drug already approved and marketed in Europe. Product deliveries under the order will begin in the present quarter.

"This is the second major paclitaxel order for Bioxel in the past month," said Pascal Delmas, President and CEO of Bioxel Pharma. "We are clearly earning customer confidence and building revenue momentum with a combination of product quality, availability and value." Mr. Delmas added, "Since June, Bioxel has landed major Paclitaxel orders with both leading generic and second generation taxane manufacturers that total $1.8 million. Over the past two years, we have had two key marketing objectives; to expand our presence in Europe and other territories outside of the US, and to diversify our customer base. These recent success demonstrate that our efforts are beginning to pay off, and that healthy growth of our Paclitaxel business is expected going forward."

This sale was predicated on Bioxel meeting the new European quality standards effective since July 2007 and it followed considerable diligence by the customer on Bioxel's Drug Master File (DMF), which is presently registered in more than 25 countries including the US, Canada, and Europe. In fact, Bioxel's product exceeds the new European quality standards, allowing the Company to sell its paclitaxel throughout this territory.


Bioxel Pharma Inc. is an emerging leader in biopharmaceuticals, focused on developing, manufacturing and marketing taxane pharmaceutical ingredients. Taxanes are used in drug products for the treatment of cancer and other diseases, including psoriasis, rheumatoid arthritis, Alzheimer's disease and cardiovascular disease. The Corporation sells cGMP paclitaxel and develops a portfolio of other generic taxane APIs and taxane-based proprietary products for improved cancer therapy.

This announcement includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect future results. These include risks and uncertainties that could affect Bioxel's products under development such as regulatory factors, technological developments and competitive factors. Achievement of the objectives set forth in this release is subject to these risks and uncertainties. The Corporation's results, or the measures it adopts, could differ materially from those indicated or underlying these statements, or could have an impact on the realization of financial projections.

The TSX Venture Exchange has not reviewed the contents of this press release and accepts no responsibility for the adequacy or the accuracy thereof.

Contact Information